In conclusion, we could optimize the engraftment capacity and the retroviral gene transfer to CD34 ؉ PBPC using cocktails of early acting cytokines in combination with the recombinant fibronectin fragment CH-296. Our data suggest that the NOD/SCID model provides a valid assay to estimate the gene transfer efficiency to repopulating human PBPC that may be achievable in clinical autologous transplantation settings. Bone Marrow Transplantation (2000) 25, Suppl. 2, S118-S124.
into hematopoietic stem (HSC) and progenitor cells (HPC) from PBPC specimens, with the objective to protect the bone marrow (BM) of cancer patients from drug-induced myelotoxicity. MDR1 encodes a membrane-located drug efflux pump, termed P-glycoprotein (PgP), which confers resistance to a wide array of cytostatic agents such as paclitaxel and etoposide. 3, 4 The xenotransplantation of human hematopoietic cells from different hematopoietic cell sources into NOD/SCID mice allowed definition of a population of human cells, termed SCID-repopulating cells (SRCs) which is capable of extensive proliferation and multilineage differentiation in vivo. 5, 6 In general, retrovirus-mediated gene transfer to SRCs has been inefficient, 5 mirroring the low levels of vector-marked cells observed in large animal models and pilot human gene therapy trials. [7] [8] [9] [10] [11] Therefore, this in vivo readout system may be a valuable tool for preclinical evaluation of human gene therapy protocols.
In this study, we retrovirally transduced CD34 ϩ PBPC from cancer patients under various culture conditions with the SF-MDR vector. 12, 13 The transduced PBPC were transplanted into NOD/SCID mice. We analyzed the human cell engraftment and the gene transfer frequency to long-term repopulating human hematopoietic cells.
Materials and methods

Selection of CD34
ϩ cells
Samples of mobilized peripheral blood apheresis cells harvested in the recovery phase after G-CSF-supported (Filgrastim; Amgen, Thousand Oaks, CA, USA) chemotherapy were obtained from 10 patients after informed consent. The study was approved by the ethical committee I of the Medical Faculty of the University of Heidelberg. CD34 ϩ PBPC were isolated following Ficoll separation and immunomagnetic CD34 ϩ selection (Miltenyi Biotec, Bergisch Gladbach, Germany). The selected fractions contained a median of 91% CD34 ϩ cells.
Retroviral Transwell transduction of CD34 ϩ PBPC
After isolation, 2 ϫ 10 6 fresh CD34 ϩ selected PBPC were seeded into six-well plates that were either not coated or coated with the recombinant fibronectin fragment CH-296 (20 g/cm 2 , RetroNectin, Takara Shuzo, Japan). Cells were transduced with the SF-MDR vector for 96 h by Transwell MDR1 gene transfer to repopulating human PBPC B Schiedlmeier et al S119 cocultivation or viral supernatant as described. 14 In the different cytokine combinations used, FL and SCF (both R& D Systems, Wiesbaden, Germany) were added to yield final concentrations of 100 ng/ml each, thrombopoietin (TPO; R&D Systems) and IL-6 (R&D Systems) were used at concentrations of 20 ng/ml each, and IL-3 (Novartis, Nürnberg, Germany) at a concentration of 50 ng/ml.
Colony-forming cell assays
CD34
ϩ cells were plated in duplicate at 5 ϫ 10 2 ml in 1 ml complete methylcellulose medium (Methocult GF, H4434, Stem Cell Technologies) containing a mixture of recombinant human cytokines. After 12-14 days of incubation at 37°C, colony-forming units granulocyte-macrophage (CFU-GM) were enumerated. Colonies (CFU-GM) were plucked and analyzed for the presence of the vector-derived MDR1 gene as described below.
Liquid culture and rhodamine (Rh-123) efflux assay
Sixty-thousand transduced or mock-transduced CD34 ϩ PBPC cells were cultured for 10 days in a cytokine cocktail containing 10 ng/ml each of SCF, IL-1␤ (IC-Chemikalien, Ismaning, Germany), IL-3, IL-6, G-CSF (Amgen, Thousand Oaks, CA, USA) and GM-CSF (IC-Chemikalien). IMDM containing 15% heat-inactivated FCS was used as culture medium. The following Rh-123 efflux assay was performed as described.
14,15
Animals
A breeding colony of NOD/LtSz-scid/scid (NOD/SCID) mice was established at the animal laboratory of the German Cancer Research Center (DKFZ) with breeding stocks originally obtained from Jackson Laboratories, Bar Harbor, ME, USA. Mice were kept under pathogen-free conditions in isolators. Five to 24 h before transplantation, 5-10-weekold female mice were conditioned by sublethal irradiation with a total dose of 3 Gy. Human CD34 ϩ PBPC were transplanted intravenously in a volume of 300 l IMDM per mouse. Starting on the day of transplantation, animals received 1-2 g human IL-3 (Novartis) and 2-4 g human G-CSF (Amgen) three times per week subcutaneously. Additionally, some of the mice received intraperitoneal injections of 250 l of phosphate-buffered saline (PBS; Gibco) containing 50 l of anti-asialo GM1 (Wako Chemicals, Neuss, Germany) immediately before transplantation; identical treatments were repeated on days 5 and 11 posttransplantation of CD34 ϩ cells.
Analysis of engraftment
Mice were killed by cervical dislocation 5-13 weeks posttransplantation of human cells. Anti-mouse CD45-fluorescein isothiocyanate (FITC; Sigma) and anti-human CD45-phycoerythrin (PE; Pharmingen, Hamburg, Germany) antibodies were used to identify the ratio of human/mouse leukocytes in the bone marrow, peripheral blood or spleen. Immediately before measurement, dead cells were excluded from analysis using propidium iodide Bone Marrow Transplantation (PI, Sigma) uptake. Samples were acquired on a Becton Dickinson FACSCalibur (10 000-20 000 events) and analyzed using the CellQuest software package.
Qualitative polymerase chain reaction analysis
CFU-GM grown in semisolid medium were individually plucked and lysed as described.
14 Nested PCR for the selective detection of the retrovirally transduced MDR1 gene (MDR1 cDNA) was performed as described elsewhere. 15 
Real-time quantitative PCR
DNA purified using the QIAamp Blood Kit was treated with 30 units RNAse A (Sigma, Deisenhofen). Triplicates of 5 l of each DNA were used as templates in a duplex PCR using the ABI PRISM 7700 Sequence Detection System (PE Applied Biosystems, Weiterstadt, Germany). In brief, primers mdr-f (5Ј AGAAAGCGAAGCAGTGG TTCA 3Ј) and mdr-r (5Ј CGAACTGTAGACAAACGAT-GAGCTA 3Ј) amplified a 90-bp fragment from the MDR1-cDNA (reaction 1) which was detected by the FAM-labeled TaqMan probe mdr-p (5Ј TGGTCCGACCTTTTCTGGCC TTATCCA 3Ј). Primers hck-f (5Ј TATTAGCAC-CATCCATAGGAGGCTT 3Ј) and hck-r (5Ј GTTAGGGA AAGTGGAGCGGAAG 3Ј) amplified a 80-bp fragment from exon1 of the human hematopoietic cell kinase 1 gene 16 (reaction 2) which was detected by the VIC-labeled TaqMan probe hck-p (5Ј TAAC-GCGTCCACCAAG-GATGCGAA 3Ј). Amplification conditions were as follows: 50°C for 2.0 min, 95°C 10 min, then 45 cycles of 95°C for 15 s, 60°C for 60 s. For each of the two reactions, the PCR cycle number generating the first fluorescence signal above a threshold (threshold cycle, CT) was determined. The difference between the CT of reaction 1 and reaction 2 (the ⌬CT value) was then used to quantify the percentage of MDR1-transduced human cells with the help of a standard curve.
Statistical analysis
The Student t-test was used to test the significance of each set of values, assuming equal variance. Mean values Ϯ 1 standard error of the mean (s.e.) are given unless stated otherwise.
Results
Initial studies of gene transfer into progenitor cells and human cell engraftment in immunodeficient mice
To establish an in vivo mouse model for the analysis of MDR1 gene transfer into human hematopoietic stem cells (HSC), we performed a first set of retroviral transduction experiments using CD34 ϩ -selected peripheral blood progenitor cells isolated from the leukapheresis products of four cancer patients. CD34
ϩ PBPC were retrovirally transduced for 96 h in the presence of IL-3 and polybrene either by Transwell cocultivation with SF-MDR1 virus producer cells in the upper chamber (two experiments) or by daily addition of fresh viral supernatant (VSNT; two experiments). Aliquots of transduced or mock-transduced CD34 ϩ PBPC were then plated into methylcellulose-based CFC assays to assess the efficiency of MDR1 gene transfer into CFU-GM progenitor cells by a provirus-specific PCR analysis. Further aliquots were cultivated in vitro for 10 days in the presence of a myeloid differentiation inducing cytokine cocktail to determine the efficiency of MDR1 gene transfer/expression in the myeloid progeny cells by applying the Rh-123 efflux assay. In addition, aliquots of 5 ϫ 10 5 and 2 ϫ 10 6 transduced and mock-transduced CD34 ϩ PBPC (day 0) were transplanted into sublethally irradiated NOD/SCID mice to study the engraftment capacity of transduced CD34 ϩ PBPC and the level of gene transfer into SCID-repopulating cells (SRCs).
In the initial four retroviral transduction experiments outlined above, the level of gene transfer into committed CFU-GM progenitor cells ranged from 5% to 50% as determined by PCR analysis of 20 single colonies per transduction sample. The proportion of Rh-123 dull cells (MDR1 expressing cells) in the myeloid progeny of MDR1-transduced CD34 ϩ PBPC ranged from 1.5% to 6.6% over the background of Rh-123 dull progeny cells derived from mock-transduced CD34 ϩ PBPC samples (example shown in Figure 1 ). Significant differences in either the proportion of PCR-positive CFU-GM colonies or the proportion of Rh-123 dull progeny cells were not observed between Transwell-and VSNTtransduced PBPC samples.
Within this set of experiments we transplanted in total 35 sublethally irradiated NOD/SCID mice with different cell numbers of either Transwell-or VSNT-transduced CD34 ϩ PBPC (Table 1 ). Five to 10 weeks after transplantation the ratio of human CD45 + /mouse CD45 ϩ leukocytes was assessed by FACS analysis in cells recovered from bone marrow (BM), spleen (Sp) and peripheral blood (PB) of the chimeric mice. Mice with less than 0.1% mouse CD45 ϩ leukocytes were regarded as non-engrafted. The results presented in Table 1 revealed a cell-dose dependent engraftment of human retrovirally transduced CD34 ϩ PBPC. Also, a clear difference between Transwell and VSNT-transduced CD34 ϩ PBPC samples became apparent, both in terms of the number of engrafted mice and the average proportion of human cells detected in all three analyzed ϩ PBPC samples were cultured for 10 days in liquid medium, containing a myeloid differentiation-inducing cytokine cocktail. Rh-123 efflux in the progeny of MDR1-and mock-transduced CD34 ϩ PBPC was determined by FACS analysis without or with inclusion of the Pglycoprotein inhibitor cyclosporin A (CsA Transwell-transduced CD34 ϩ PBPC (Table 1 ) recovered chimeric BM cells were plated into human-specific CFC assays. Twenty human myeloid colonies (CFU-GM, CFU-M) were then plucked from the culture dishes and subjected to a MDR1 provirusspecific PCR analysis. In two of the three BM samples we were able to detect four or 10 provirus-marked colonies, respectively, out of each of the 20 analyzed human colonies (Figure 2A ), indicating MDR1 gene transfer rate of 25% and 50% to repopulating human progenitor cells.
Quantitative assessment of MDR1 gene transfer into SRCs
Based on this experience, we decided to investigate in more detail to what extent the engraftment capacity of CD34 ϩ PBPC, ie into committed progenitor cells and longterm SRCs in the new set of experiments, we coated the surface of the lower chamber of the Transwell set with the recombinant fibronectin fragment CH-296 (Retronectin), previously reported to improve transduction rates by colocalization of hematopoietic cells and retroviral particles. 17, 18 In addition to preconditioning the mice by sublethal irradiation and administration of recombinant human IL-3 and G-CSF, all NOD/SCID mice further received three MDR1 gene transfer to repopulating human PBPC B Schiedlmeier et al S121 In the presence of IL-3 (50 ng/ml) and polybren (4 g/ml), several aliquots of 2 ϫ 10 6 CD34 ϩ PBPC from each patient sample were either transduced for 96 h by daily addition of SF-MDR virus containing supernatant (VSNT) or by Transwell cocultivation with 1 ϫ 10 5 SF-MDR virus producer cells in the upper chamber of the set up. Subsequent to cell harvest, CD34
ϩ PBPC from identical patient donors separately transduced under otherwise identical conditions were combined before injection of the cells into preconditioned NOD/SCID mice. In parallel, methylcellulose-based CFC assays and liquid myeloid-differentiation cultures for the Rh-123 efflux assays were initialized. Five to 10 weeks post transplantation the ratio of human/mouse CD45 ϩ leukocytes was determined by FACS in cells recovered from BM, Sp and PB of the transplanted NOD/SCID mice. Mice with a ratio of human/mouse CD45 ϩ leukocytes Ͻ0.1% were classified as non-engrafted. The proportion of human CD45 ϩ leukocytes in the engrafted mice is shown in brackets as mean values Ϯ s.e. Figure 3 ) were subjected to real-time duplex PCR in triplicates. In Table 2 , the average levels of MDR1 gene transfer/expression before transplantation into the NOD/SCID mice are juxtaposed to the observed average proportion of human cell engraftment and the extent of vector-marked human leukocytes for the four cytokine transductions groups. The level of gene transfer into myeloid committed progenitors and the proportion of Rh-123 dull myeloid progeny Transwell cocultures of 2 ϫ 10 6 CD34 ϩ PBPC with 1 ϫ 10 5 SF-MDR virus producer cells were performed for 96 h in the presence of fibronectin and the indicated cytokines. CD34 ϩ PBPC samples from identical patients separately transduced under otherwise identical conditions were combined at the time of harvest before injection of the cells into a given number of NOD/SCID mice. Parallel, CFC assays and liquid myeloid-differentiation cultures were set up. Bone marrow (BM) was recovered from chimeric NOD/SCID mice 5 to 13 weeks post-transplantation and the proportion of human CD45 cells ranged from 6% to 45% and 0.7% to 7.1%, respectively, without statistically significant difference between the various transduction groups. Similarly, the average level of human cell engraftment in the marrow of this new set of NOD/SCID mice transplanted with CD34 ϩ PBPC that were transduced in the presence of fibronectin plus either IL-3, IL-3/FL, IL-3/IL-6/SCF/FL or FL/TPO/SCF were not statistically different and ranged from 8.4% to 32.6% human leukocytes ( Table 2 ; example shown in Figure 4 ). Interestingly, the average level of human cell engraftment in mice transplanted with 2 ϫ 10 6 CD34
ϩ PBPC Transwell-transduced in the presence of IL-3 plus fibronectin was several-fold higher (32.6% Ϯ 11.0%) compared to that seen in the previous set of mice transplanted with a similar number of CD34 ϩ PBPC Transwell-trans- duced in the presence of IL-3 without fibronectin (8.6% Ϯ 6.7%; Table 1 ). Likewise, mice of the IL-3/FLand IL-3/IL-6/SCF/FL-transduction groups also showed a higher average level of human cell engraftment than the IL-3 transduction group without fibronectin. Since at the same time, we included fibronectin and treated the new set of mice with antibodies against mouse NK cells, we can not discern the role of each parameter in improving human cell engraftment. The extent of vector-marked human cells in the marrow of 22 engrafted mice ranged from below 0.1% up to 30% (Table 2) . Significantly higher average proportions of vector-marked human cells were detected in the marrow of mice transplanted with CD34 ϩ PBPC transduced in the presence of fibronectin plus either IL-3/IL-6/SCF/FL or FL/TPO/SCF than in one of the other two transduction groups. SF-MDR provirus integration was optimal in the presence of IL-3/IL-6/SCF/FL or FL/TPO/SCF resulting in three-fold or four-fold higher average proportions of vectormarked human cells in NOD/SCID mice compared to IL-3 alone. Comparable rates of vector-marked HuCFCs derived from corresponding individual chimeric BM samples from mice of the FL/TPO/SCF transduction group were found (data not shown), confirming the results from the real-time duplex PCR technique.
Discussion
In this study, we show engraftment of MDR1-transduced PBPC from cancer patients in NOD/SCID mice. By either Transwell cocultivation of CD34
ϩ PBPC with vector-producing cells or by viral supernatant transduction (VSNT) we achieved gene transfer efficiencies of up to 50% in clonogenic progenitors, similar to those reported previously by other groups. 19, 20 To analyze the engraftment capacity of transduced CD34
ϩ PBPC and to document gene transfer into human cells with in vivo repopulating potential, sublethally irradiated NOD/SCID mice were transplanted with 0.5 or 2.0 ϫ 10 6 CD34 ϩ cells. In our initial NOD/SCID experiments, even transplantation of 2.0 ϫ 10 6 CD34 ϩ PBPC transduced with VSNT in the presence of IL-3 and polybrene resulted in very low average levels of human cell engraftment (Ͻ1%), whereas transplantation of 2.0 ϫ 10 6 CD34 ϩ PBPC Transwell-transduced under otherwise identical conditions yielded a 21-fold higher average level of human cell chimerism (8.6%). Though we can not exclude that the poor engraftment levels that we observed with VSNT-transduced CD34 ϩ PBPC are mainly the consequence of a major cell loss due to the multiple centrifugation steps, similar findings reported by Germeraad et al 21 for retrovirally transduced mouse hematopoietic stem cells argue against this possiblity. The engraftment capacity of Transwell-transduced CD34 ϩ PBPC could be further improved several-fold by coating the culture dishes with fibronectin in combination with treatment of the mice with anti-asialo GM1 antibodies directed against mouse NK cells, resulting in average levels of up to 33% human leukocytes in the marrow (Table 2) .
Recent data reported by the group of Nolta proved that adhesion to the recombinant fibronectin fragment CH-296 through engagement of VLA-4 and VLA-5 integrins during ex vivo culture was as effective as BM stromal cells in supporting the long-term engraftment potential of human HSC/HPCs. 22 Thus, the use of FN-coated culture dishes in conjunction with administration of anti-asialo GM1 and human cytokines may have been the important factors responsible for the high level of human cell engraftment observed in our study.
Our data are consistent with levels of human cell engraftment reported by Hogan et al 23 for freshly isolated CD34 ϩ PBPC from cancer patients transplanted into NOD/SCID mice at comparable graft sizes and under quite similar NOD/SCID mouse conditioning including i.p. injections of anti-asialo GM1 antibodies and administration of cytokines. In contrast to these results, significantly lower levels of human cell engraftment in NOD/SCID mice have and/or the treatment of mice with anti-asialo GM1 24 may account for these differences. Similar levels of human cell engraftment in NOD/SCID mice to those reported here have been reported by groups after retroviral infection over comparable short-term cultivation periods, using mononuclear and/or CD34-selected cord blood (CB) cells, 5, 24, 25 which have a higher engraftment potential in NOD/SCID mice. 25 The development of a quantitative real-time duplex PCR technique allowed us to monitor the proportion of MDR1-transduced human cells in the BM of chimeric mice. The average proportion of vector-marked human cells in mice ranged from 4.1% to 16.5% ( Table 2 ), indicating that these mice were engrafted with one or more transduced SRCs. Recently, clinically relevant gene transfer rates of 10% to 20% of in vivo repopulating cells present in mobilized PB of two different non-human primates (rhesus macaques, baboons) have been achieved. In these two studies both the target cell population (CD34 ϩ PBPC) and the short-term retroviral transduction protocols were similar to our study. Therefore, our data may indicate for the first time that the NOD/SCID model is a valid assay to measure gene transfer to repopulating human HSC obtained from mobilized PB, and is comparable to autologous transplantation in large animal models. This underlines the relevance of murine in vivo surrogate assays for optimizing clinically applicable protocols for the transduction and ex vivo expansion of primitive human hematopoietic cells. Recently, efficient levels of gene transfer to primitive in vivo repopulating human CD34 ϩ cells in cord blood have also been reported by several other groups in NOD/SCID mice. [25] [26] [27] However, no comparable studies in primates or humans have been published with cord blood to validate these data.
In conclusion, our results demonstrate that potentially clinically relevant efficiencies of gene transfer in repopulating human hematopoietic stem cells are now achievable using combinations of early acting cytokines in combination with the recombinant fibronectin fragment CH-296.
